Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Core Insights - Cidara Therapeutics will present two oral presentations, including a late-breaking abstract, at the ISRV 8th AntiViral Group Meeting and 3rd International Meeting on Respiratory Pathogens in Singapore from September 17-20, 2025 [1][2] Group 1: Presentation Details - The late-breaking abstract titled "NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Trial to Evaluate the Efficacy and Safety of CD388 for Prevention of Influenza Illness in Healthy Adults" will be presented by Dr. Rick Bright on September 17, 2025, from 3:50 – 4:05 p.m. SGT [2] - Another abstract titled "A Single Prophylactic dose of CD388 Provides Protection Against Highly Pathogenic Bovine-Origin Influenza A (H5N1) Virus in the Ferret Model" will be presented by Dr. Andreev Konstantin on September 19, 2025, from 10:30 a.m. – 12:30 p.m. SGT [2] Group 2: Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, with its lead candidate CD388 designed for universal prevention of seasonal and pandemic influenza with a single dose [3] - CD388 received Fast Track Designation from the FDA in June 2023 and positive top-line results from its Phase 2b NAVIGATE trial were announced in June 2025 [3]